🇺🇸 SECLakefront Biotherapeutics NVCodex · 实盘不做把握 6/10不做原因:无增量信息
北京时间·🕒 发布 04:59:23·⟳ 抓取 05:00:27 +1m04s·⚡ 决策 09-02 06:23:06 +1h22m·55.5 天前
Lakefront Biotherapeutics披露8月24日至28日回购127,796股自有股份
事件方向偏正面但增量弱，属于既有回购计划下的例行买回披露；在未取得实时行情、先例和已处理事件检查的情况下，不能给出可回测的ENTER订单。
📄 原文Lakefront Biotherapeutics NV↗ 原文
----- f6k_090126.htm ----- 6-K 1 f6k_090126.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D…
不做 Lakefront Biotherapeutics NV（LKFT.US）
既有回购计划的例行执行披露，新增预期差不足；且未取得真实行情、市值和先例校准，不能形成可执行订单。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
SEC 6-K显示Lakefront在既有回购计划内一周回购127,796股、约321.9万欧元。该信息确认公司持续回购，但不是新授权、上调回购规模或临床/商业化进展，短线预期差和基本面弹性不足，因此回避。
🔎 新鲜度:最早出现 2026-09-01 · 扩散 low · price-in 风险 medium ↗
关键理由
- 回购执行对存量股东边际正面，但本次披露只是6月9日计划下的周度执行。
- 披露金额为321.9万欧元，未能在当前材料中量化为足以驱动短线重估的市值比例。
主要风险
- 未取得真实行情与市值，无法校准金额占比、price-in和可执行价格。
- 若公司后续披露扩大回购授权或重大管线进展，当前回避结论需重评。
反向证据
- 做多前查反向 · 来源 filing · 日期 2026-09-01 · 影响 weakens
披露只说明既有计划下回购执行，未见新增授权、提高回购规模或管线基本面增量。
检索:Lakefront Biotherapeutics 2026 share repurchase 127,796 shares materiality market cap 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例不足叠加事件增量弱，使本次不进入交易。
方向:未完成可验证同类先例研究；例行回购执行通常只能辅助正向判断，不能单独支持交易。
涨幅量级:缺少同市场同机制且锚点干净的高相似先例，不能据此设定tp/sl。
形态:未取得样本，无法判断是否存在见光死或高开低走模式。
原文全文
展开原文 · 6,724 字
----- f6k_090126.htm -----
6-K
1
f6k_090126.htm
FORM 6-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of September 2026
Commission File Number:
001-37384
Lakefront Biotherapeutics
(Translation of registrant's name into English)
Schaliënhoevedreef 20T, 2800 Mechelen, Belgium
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ] Form 40-F [ ]
The information contained in this Report on Form 6-K, including Exhibit 99.1, is hereby incorporated by reference into the Company's Registration Statements on Form S-8 (File Nos. 333-204567, 333-208697, 333-211834, 333-215783, 333- 218160, 333-225263, 333-231765, 333-249416, 333-260500, 333-268756, 333-275886, 333-283361, and 333-292050).
On September 1, 2026, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Exhibit 99.1. Press release dated September 1, 2026
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Lakefront Biotherapeutics
(Registrant)
Date: September 1, 2026
/s/ Ying Deng
Ying Deng
Authorized Officer
----- exh_991.htm -----
EX-99.1
2
exh_991.htm
PRESS RELEASE
EdgarFiling
EXHIBIT 99.1
Acquisition of Own Shares
Mechelen, Belgium; 01 September 2026, 22.01 CET; regulated information
Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext &
NASDAQ: LKFT) ("Lakefront") announces that between August 24, 2026 and August 28, 2026 it has repurchased 127,796 Lakefront shares via
a discretionary mandate to an independent financial intermediary, as follows:
Date
of purchase
Market/MTF
Number
of shares
Average
price paid (€)
Total
(€)
Lowest
price paid (€)
Highest
price paid (€)
24/08/2026
XAMS
21,820
24.56
535,857.74
24.36
24.64
24/08/2026
TQEX
450
24.55
11,045.43
24.54
24.60
24/08/2026
CEUX
328
24.58
8,062.37
24.54
24.64
24/08/2026
AQEU
1,333
24.61
32,811.40
24.58
24.66
25/08/2026
XAMS
21,058
25.29
532,464.16
24.94
25.52
25/08/2026
TQEX
698
25.25
17,623.66
25.00
25.36
25/08/2026
CEUX
600
25.28
15,165.48
25.24
25.34
25/08/2026
AQEU
313
25.29
7,914.33
25.26
25.34
26/08/2026
XAMS
22,968
25.45
584,632.07
25.08
25.64
26/08/2026
TQEX
599
25.45
15,241.91
25.30
25.64
26/08/2026
CEUX
1,703
25.47
43,377.62
25.24
25.66
26/08/2026
AQEU
539
25.50
13,744.72
25.32
25.60
27/08/2026
XAMS
21,382
25.27
540,406.53
25.06
25.36
27/08/2026
TQEX
904
25.27
22,843.72
25.20
25.32
27/08/2026
CEUX
2,342
25.24
59,114.89
25.12
25.36
27/08/2026
AQEU
440
25.23
11,100.50
25.12
25.34
28/08/2026
XAMS
25,694
25.29
649,927.16
25.00
25.50
28/08/2026
TQEX
1,110
25.40
28,194.11
25.36
25.46
28/08/2026
CEUX
3,363
25.38
85,342.18
25.08
25.46
28/08/2026
AQEU
152
25.26
3,840.17
25.14
25.46
Total
127,796
25.19
3,218,710.15
24.36
25.66
As of market close on 28 August 2026, Lakefront holds 1,161,324 of its own ordinary shares.
About Lakefront Biotherapeutics
Lakefront Biotherapeutics is a biotechnology company dedicated
to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need. The Company has established
a clinical‑stage portfolio in immunology and inflammation, anchored by gamgertamig, a potential first‑in‑class and best-in-class
BCMAxCD3 T‑cell engager for autoimmune diseases. Backed by deep deal‑making expertise, operational flexibility, and a strong
capital position, Lakefront identifies, acquires, and advances high‑quality assets with clear potential to deliver meaningful patient
impact and long‑term shareholder value. For more information, visit https://www.lakefrontbio.com or follow us on LinkedIn or X.
For further information, contact Lakefront Biotherapeutics:
Investor Relations
Sherri
Spear
+1 412 522 6418
sherri.spear@lakefrontbio.com
Forward-looking statements
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995, all of which involve certain risks and uncertainties. These statements
are often, but are not always, made through the use of words or phrases such as “believe,” “anticipate,” “expect,”
“intend,” “plan,” “seek,” “upcoming,” “future,” “estimate,” “may,”
“will,” “could,” “would,” “potential,” “forward,” “goal,” “next,”
“continue,” “should,” “encouraging,” “aim,” “progress,” “remain,”
“explore,” and “further,” as well as similar expressions. These statements include, but are not limited to, statements
regarding Lakefront’s plans to repurchase its ordinary shares. Lakefront cautions the reader that forward-looking statements are
based on our management’s current expectations and beliefs and are not guarantees of future performance. Forward-looking statements
may involve known and unknown risks, uncertainties and other factors which might cause actual events, financial condition and liquidity,
performance, or achievements, or the industry in which we operate, to be materially different from any historic or future results, financial
conditions, performance or achievements expressed or implied by such forward-looking statements. In addition, even if our results, performance,
financial condition and liquidity, and the development of the industry in which Lakefront operates are consistent with such forward-looking
statements, they may not be predictive of results or developments in future periods. Such risks include, but are not limited to, those
risks and uncertainties that can be found in our filings and reports with the Securities and Exchange Commission (“SEC”),
including in our most recent annual report on Form 20-F filed with the SEC and our subsequent filings and reports filed with the SEC.
Given these risks and uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. In addition,
even if the result of our operations, financial condition and liquidity, or the industry in which we operate, are consistent with such
forward-looking statements, they may not be predictive of results, performance or achievements in future periods. These forward-looking
statements speak only as of the date of publication of this release. We expressly disclaim any obligation to update any such forward-looking
statements in this release to reflect any change in our expectations or any change in events, conditions or circumstances, unless specifically
required by law or regulation.
6-K
1
f6k_090126.htm
FORM 6-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of September 2026
Commission File Number:
001-37384
Lakefront Biotherapeutics
(Translation of registrant's name into English)
Schaliënhoevedreef 20T, 2800 Mechelen, Belgium
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ] Form 40-F [ ]
The information contained in this Report on Form 6-K, including Exhibit 99.1, is hereby incorporated by reference into the Company's Registration Statements on Form S-8 (File Nos. 333-204567, 333-208697, 333-211834, 333-215783, 333- 218160, 333-225263, 333-231765, 333-249416, 333-260500, 333-268756, 333-275886, 333-283361, and 333-292050).
On September 1, 2026, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Exhibit 99.1. Press release dated September 1, 2026
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Lakefront Biotherapeutics
(Registrant)
Date: September 1, 2026
/s/ Ying Deng
Ying Deng
Authorized Officer
----- exh_991.htm -----
EX-99.1
2
exh_991.htm
PRESS RELEASE
EdgarFiling
EXHIBIT 99.1
Acquisition of Own Shares
Mechelen, Belgium; 01 September 2026, 22.01 CET; regulated information
Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext &
NASDAQ: LKFT) ("Lakefront") announces that between August 24, 2026 and August 28, 2026 it has repurchased 127,796 Lakefront shares via
a discretionary mandate to an independent financial intermediary, as follows:
Date
of purchase
Market/MTF
Number
of shares
Average
price paid (€)
Total
(€)
Lowest
price paid (€)
Highest
price paid (€)
24/08/2026
XAMS
21,820
24.56
535,857.74
24.36
24.64
24/08/2026
TQEX
450
24.55
11,045.43
24.54
24.60
24/08/2026
CEUX
328
24.58
8,062.37
24.54
24.64
24/08/2026
AQEU
1,333
24.61
32,811.40
24.58
24.66
25/08/2026
XAMS
21,058
25.29
532,464.16
24.94
25.52
25/08/2026
TQEX
698
25.25
17,623.66
25.00
25.36
25/08/2026
CEUX
600
25.28
15,165.48
25.24
25.34
25/08/2026
AQEU
313
25.29
7,914.33
25.26
25.34
26/08/2026
XAMS
22,968
25.45
584,632.07
25.08
25.64
26/08/2026
TQEX
599
25.45
15,241.91
25.30
25.64
26/08/2026
CEUX
1,703
25.47
43,377.62
25.24
25.66
26/08/2026
AQEU
539
25.50
13,744.72
25.32
25.60
27/08/2026
XAMS
21,382
25.27
540,406.53
25.06
25.36
27/08/2026
TQEX
904
25.27
22,843.72
25.20
25.32
27/08/2026
CEUX
2,342
25.24
59,114.89
25.12
25.36
27/08/2026
AQEU
440
25.23
11,100.50
25.12
25.34
28/08/2026
XAMS
25,694
25.29
649,927.16
25.00
25.50
28/08/2026
TQEX
1,110
25.40
28,194.11
25.36
25.46
28/08/2026
CEUX
3,363
25.38
85,342.18
25.08
25.46
28/08/2026
AQEU
152
25.26
3,840.17
25.14
25.46
Total
127,796
25.19
3,218,710.15
24.36
25.66
As of market close on 28 August 2026, Lakefront holds 1,161,324 of its own ordinary shares.
About Lakefront Biotherapeutics
Lakefront Biotherapeutics is a biotechnology company dedicated
to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need. The Company has established
a clinical‑stage portfolio in immunology and inflammation, anchored by gamgertamig, a potential first‑in‑class and best-in-class
BCMAxCD3 T‑cell engager for autoimmune diseases. Backed by deep deal‑making expertise, operational flexibility, and a strong
capital position, Lakefront identifies, acquires, and advances high‑quality assets with clear potential to deliver meaningful patient
impact and long‑term shareholder value. For more information, visit https://www.lakefrontbio.com or follow us on LinkedIn or X.
For further information, contact Lakefront Biotherapeutics:
Investor Relations
Sherri
Spear
+1 412 522 6418
sherri.spear@lakefrontbio.com
Forward-looking statements
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995, all of which involve certain risks and uncertainties. These statements
are often, but are not always, made through the use of words or phrases such as “believe,” “anticipate,” “expect,”
“intend,” “plan,” “seek,” “upcoming,” “future,” “estimate,” “may,”
“will,” “could,” “would,” “potential,” “forward,” “goal,” “next,”
“continue,” “should,” “encouraging,” “aim,” “progress,” “remain,”
“explore,” and “further,” as well as similar expressions. These statements include, but are not limited to, statements
regarding Lakefront’s plans to repurchase its ordinary shares. Lakefront cautions the reader that forward-looking statements are
based on our management’s current expectations and beliefs and are not guarantees of future performance. Forward-looking statements
may involve known and unknown risks, uncertainties and other factors which might cause actual events, financial condition and liquidity,
performance, or achievements, or the industry in which we operate, to be materially different from any historic or future results, financial
conditions, performance or achievements expressed or implied by such forward-looking statements. In addition, even if our results, performance,
financial condition and liquidity, and the development of the industry in which Lakefront operates are consistent with such forward-looking
statements, they may not be predictive of results or developments in future periods. Such risks include, but are not limited to, those
risks and uncertainties that can be found in our filings and reports with the Securities and Exchange Commission (“SEC”),
including in our most recent annual report on Form 20-F filed with the SEC and our subsequent filings and reports filed with the SEC.
Given these risks and uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. In addition,
even if the result of our operations, financial condition and liquidity, or the industry in which we operate, are consistent with such
forward-looking statements, they may not be predictive of results, performance or achievements in future periods. These forward-looking
statements speak only as of the date of publication of this release. We expressly disclaim any obligation to update any such forward-looking
statements in this release to reflect any change in our expectations or any change in events, conditions or circumstances, unless specifically
required by law or regulation.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。